PIM1

(Pim-1 oncogene)

 

  • Alias                                 (According to NCBI)

 
  • PIM1
  • PIM

 
  • May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Isoform promotes the G1/S transition of the cell cycle via up-regulation of CDK2 activity and phosphorylation of CDKN1B, resulting in enhanced nuclear export and proteasome-dependent degradation of CDKN1B. Isoform 2 also represses CDKN1B transcription by phosphorylating and inactivating the transcription factor FOXO3. Plays a role in signal transduction in blood cells. Contributes to both cell proliferation and survival and thus provides a selective advantage in tumorigenesis
  • Location:6p21.2
  • Size:5283 bp
  • exons:
  • DNA sequence (Human):  NC_000006

 

 

 

 

  • CGH (6p21.2):  Losses (%) -1.1   Gain (%) 9.5    

 
  • Mutations and SNPs (According to HGMD and SNP)

 

 
  • m-RNA                       (According to NCBI and CGAP)

 

  • mRNA sequence (Human):  NM_002648

  • Size: 2751 bp

  • cDNA libraries:
  • Size:404 amino acids; 45412 Da
  • Catalytic activity: ATP + a protein = ADP + a phosphoprotein.

  • Subcellular location: Cytoplasm. Nucleus

  • Protein domains

     

  • Protein sequence (Human): P11309

  • Homologous genes:

  • 2D PAGE:

  • 3D Structure: 1XQZ

  • PTM: PIM1
  • Pathways and interactions (According to BioCarta, DIP)

  • Pathway:

  • Protein interactions: P11309
  • Clinical                            (According to OMIM, PubMed)